Dr. James Todaro, who joined Frontline Doctors in DC in July voicing the effect of hydroxychloroquine (HCQ), tweeted on August 29 that Gilead, the maker of Remdesivir, was back down to its pre-pandemic price. He suggested that the reason was because “The studies on Remdesivir never looked that great.”
Back in April, Professor Didier Raoult, a renowned virologist and physician in France made a connection between Gilead stock price with HCQ when he was interviewed by Dr. Oz. Based on this theory, the low stock price of Gilead could also be related to the evolving evidence of the effectiveness the availability of HCQ.
A clip of Dr. Raoult’s interview:
Dr. Raoult: It seems like it’s become very political.
Dr. Oz: Why do you think there is so much debate over hydroxychloroquine? Not only. Did you see if you want to … One of the, one of the question – not the only one question – but one of the question is the value of the action of Gilead. Look at the … when you talk about chloroquine what is the level of the action of Gilead. It’s just dependent if you talk about chloroquine.
Dr. Oz: I missed their point, I’m sorry. Why is there so much debate over hydroxychloroquine? I see this in South America and Asia. I see it in Europe. I see it in the United States.
Dr. Raoult: Yeah, one of the thing is that probably the monster, the big actor was in these all action is Gilead. Ok? Remdesivir. And as soon as the outbreak start, the action value capitalization of Gilead jumped by 15 or 17 percent, and at each time when you talk about chloroquine, it falling down. There is several factors, and this one is a big one.
Presented by the VOG Rose Garden Team